Annual report pursuant to Section 13 and 15(d)

Note 17 - Income Taxes (Tables)

v3.19.1
Note 17 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2018
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   
As of December 31,
 
   
2018
   
2017
 
Deferred tax assets:
               
Net operating loss carryforwards
  $
29,597,313
    $
29,570,581
 
R&D credit carryforwards
   
9,067,874
     
10,043,714
 
AMT credit carryforward
   
621,240
     
1,229,979
 
Stock compensation
   
375,731
     
576,024
 
Intangibles
   
550,797
     
591,651
 
Gain/loss from discontinued operations
   
     
(2,510,699
)
Disallowed interest expense
   
878,929
     
 
Temporary differences
   
480,888
     
207,447
 
Deferred tax assets before valuation allowance
   
41,572,772
     
39,708,697
 
Valuation allowance
   
(40,951,532
)
   
(38,478,718
)
Net deferred tax assets
  $
621,240
    $
1,229,979
 
Summary of Tax Credit Carryforwards [Table Text Block]
       
As of December 31, 201
8
 
Generated
 
Expiration
 
U.S.
Net
Operating
Loss
Carryforwards
   
U.S.
R&D
Credit
Carryforwards
 
1999
 
2019
  $
    $
130,359
 
2000
 
2020
   
     
71,713
 
2001
 
2021
   
     
39,128
 
2002
 
2022
   
     
5,350
 
2003
 
2023
   
     
2,905
 
2004
 
2024
   
     
22,861
 
2005
 
2025
   
     
218,332
 
2006
 
2026
   
     
365,541
 
2007
 
2027
   
     
342,898
 
2008
 
2028
   
     
531,539
 
2009
 
2029
   
     
596,843
 
2010
 
2030
   
     
1,094,449
 
2011
 
2031
   
     
1,950,744
 
2012
 
2032
   
18,684,249
     
468,008
 
2013
 
2033
   
37,450,522
     
681,772
 
2014
 
2034
   
34,088,874
     
816,116
 
2015
 
2035
   
25,073,846
     
492,732
 
2016
 
2036
   
15,581,209
     
262,257
 
2017
 
2037
   
     
387,892
 
2018  
2038
   
     
197,547
 
Total carryforwards
  $
130,878,700
    $
8,678,986
 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
2018
   
2017
 
   
Amount
   
%
   
Amount
   
%
 
Benefit at statutory rate
  $
(3,383,491
)
   
(21.0
)%
  $
(6,048,423
)
   
(34.0
)%
Adjustments to valuation allowance
   
2,458,580
     
15.3
%
   
(26,080,051
)
   
(146.6
)%
Adjustments to R&D credit carryforwards
   
975,840
     
6.1
%
   
(291,745
)
   
(1.6
)%
Tax law changes
   
     
     
28,731,045
     
161.5
%
Permanent items and other
   
(60,682
)
   
(0.3
)%
   
(373,315
)
   
(2.2
)%
Benefit per financial statements
  $
(9,753
)    
 
    $
(4,062,489
)